Age-stratified normal values for prostate volume, PSA, maximum urinary flow rate, IPSS, and other LUTS/BPH indicators in the German male community-dwelling population aged 50 years or older
- 1.4k Downloads
To establish age-stratified normal values for prostate volume, serum total prostate-specific antigen (PSA) concentration, maximum urinary flow rate (Q max), micturition and postvoid residual urine volumes, IPSS, and quality of life. These community-derived values of healthy older men are necessary to correctly judge patients with lower urinary tract symptoms due to benign prostatic hyperplasia (LUTS/BPH).
Analysis of LUTS/BPH-related determinants in community-dwelling men in the city of Herne, Germany after exclusion of subgroups with co-morbidities or co-medications with possible influence on the key items.
The analysis is based on 1,763 participants. In these men aged 50–80 years, mean total prostate volume continuously increased from 24 to 38 cc and mean PSA concentration from 1.1 to 2.5 ng/ml. PSA concentration in men with a prostate volume <25 cc also showed a continuous increase with aging, starting at 0.8 in the youngest and ending at 1.9 ng/ml in the oldest age group. Mean Q max of free uroflowmetry (from 22.1 to 13.7 ml/s) and mean micturition volume (from 329 to 193 cc) showed a continuous decrease that was dependent on prostate size. Mean postvoid residual urine was nearly unchanged over the age groups at approximately 20–30 cc. Although IPSS increased continuously with aging (from 4 to 7), QoL remained unchanged at 2 over the age groups. Prostate size had a minor impact on IPSS.
Normal values for investigated LUTS/BPH-related determinants and the influence of aging hereon should serve as references during the assessment of Caucasian patients in Europe.
KeywordsBenign prostatic hyperplasia Epidemiology Lower urinary tract symptoms Community-based participatory research Diagnosis Prostate-specific antigen Uroflowmetry Aging
Benign prostatic enlargement
Benign prostatic hyperplasia
International prostate symptom score
Lower urinary tract symptoms
Maximum urinary flow rate
Quality of life derived from IPSS
Conflict of interest
The authors declare no conflict of interest.
- 1.Berges R (2008) Epidemiology of benign prostatic syndrome. Associated risks and management data in German men over age 50. Der Urologe Ausg 47(2):141–148Google Scholar
- 4.Berges R, Dreikorn K, Hofner K, Madersbacher S, Michel MC, Muschter R, Oelke M, Reich O, Rulf W, Tschuschke C, Tunn U (2009) Diagnostic and differential diagnosis of benign prostate syndrome (BPS): guidelines of the German Urologists. Der Urologe Ausg 48 (11):1356–1360, 1362–1364Google Scholar
- 8.Speakman M, Batista J, Berges R, Chartier-Kastler E, Conti G, Desgrandchamps F, Dreikorn K, Lowe F, O’Leary M, Perez M, Trachtenberg J, Tubaro A, Meesen B, Smets L, Stoevelaar H (2005) Integrating risk profiles for disease progression in the treatment choice for patients with lower urinary tract symptoms/benign prostatic hyperplasia: a combined analysis of external evidence and clinical expertise. Prostate Cancer Prostatic Dis 8(4):369–374PubMedCrossRefGoogle Scholar
- 11.Hutchison A, Farmer R, Chapple C, Berges R, Pientka L, Teillac P, Borkowski A, Dobronski P (2006) Characteristics of patients presenting with LUTS/BPH in six European countries. Eur Urol 50(3):555–561 (discussion 562)Google Scholar
- 12.Bosch JL, Bangma CH, Groeneveld FP, Bohnen AM (2008) The long-term relationship between a real change in prostate volume and a significant change in lower urinary tract symptom severity in population-based men: the Krimpen study. Eur Urol 53(4):819–825 (discussion 825–817)Google Scholar
- 19.Wirth M (2010) Die neue Leitlinie zum Prostatakarzinom. Der Urologe Ausg 49(2):171–172Google Scholar
- 22.Kawachi MH, Bahnson RR, Barry M, Carroll PR, Carter HB, Catalona WJ, Epstein JI, Etzioni RB, Hemstreet GP III, Howe RJ, Kopin JD, Lange PH, Lilja H, Mohler J, Moul J, Nadler RB, Patterson S, Pollack A, Presti JC, Stroup AM, Urban DA, Wake R, Wei JT (2007) Prostate cancer early detection. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 5(7):714–736PubMedGoogle Scholar
- 28.Roehrborn CG, Bruskewitz R, Nickel JC, McConnell JD, Saltzman B, Gittelman MC, Malek GH, Gottesman JE, Suryawanshi S, Drisko J, Meehan A, Waldstreicher J (2004) Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia. J Urol 171(3):1194–1198PubMedCrossRefGoogle Scholar